Incidence and clinical features of Clostridium difficile infection in Korea: A nationwide study

Epidemiology and Infection

Volumn 141, Issue 1, 2013, Pages 189-194

  Kim, Y S ^a   Han, D S ^b   Kim, Y H ^c   Kim, W H ^d   Kim, J S ^e   Kim, H S ^f,g   Park, Y S ^h   Song, H J ⁱ   Shin, S J ^j   Yang, S K ^k   Ye, B D ^k   Eun, C S ^b   Lee, K M ^l   Lee, S H ^a   Jang, B I ^m   Jung, S A ⁿ   Cheon, J H ^d   Choi, C H ^o   Huh, K C ^p,q  

^a Inje University College of Medicine   (South Korea)

^b Hanyang University College of Medicine   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e Seoul National University College of Medicine   (South Korea)

^f Chonnam National University Medical School   (South Korea)

^g Yonsei University Wonju College of Medicine   (South Korea)

^h Eulji University   (South Korea)

ⁱ Jeju National University School of Medicine   (South Korea)

^j Ajou University School of Medicine   (South Korea)

^k University of Ulsan College of Medicine   (South Korea)

^l The Catholic University of Korea College of Medicine   (South Korea)

^m Yeungnam University College of Medicine   (South Korea)

ⁿ Ewha Womans University School of Medicine   (South Korea)

^o Chung Ang University College of Medicine   (South Korea)

^p Konyang University College of Medicine   (South Korea)

^q IBD Study Group of the Korean Association   (South Korea)

more..

Author keywords

Clostridium difficile infection; incidence; Korea

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; METRONIDAZOLE; PENICILLIN DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TUBERCULOSTATIC AGENT; VANCOMYCIN;

ADULT; AGED; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COMORBIDITY; ENDOSCOPY; ENZYME IMMUNOASSAY; FECES CULTURE; FEMALE; HUMAN; INCIDENCE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; RECURRENCE RISK; SOUTH KOREA; TREND STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; FEMALE; HOSPITALS; HUMANS; INCIDENCE; KOREA; MALE; METRONIDAZOLE; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84870895746     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268812000581     Document Type: Article

References (30)

1. McFarland LV, et al. Nosocomial acquisition of Clostridium difficile infection. New England Journal of Medicine 1989; 320: 204-210. (Pubitemid 19034145)
2. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. New England Journal of Medicine 1994; 330: 257-262. (Pubitemid 24034138)
3. Pepin J, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: A changing pattern of disease severity. Canadian Medical Association Journal 2004; 171: 466-472. (Pubitemid 39179608)
4. Ricciardi R, et al. Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Archives of Surgery 2007; 142: 624-631. (Pubitemid 47080440)
5. O'Connor JR, Johnson S, Gerding DN. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology 2009; 136: 1913-1924.
6. Warny M, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366: 1079-1084. (Pubitemid 41338761)
7. Miller MA, et al. Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals. Infection Control and Hospital Epidemiology 2002; 23: 137-140. (Pubitemid 34246541)
8. Kyne L, et al. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clinical Infectious Disease 2002; 34: 346-353. (Pubitemid 34062235)
9. Muto CA, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infection Control and Hospital Epidemiology 2005; 26: 273-280. (Pubitemid 40445086)
10. Byun TJ, et al. Clinical characteristics and changing epidemiology of Clostridium difficile-associated disease (CDAD). Korean Journal of Gastroenterology 2009; 54: 13-19.
11. Lee JH, et al. The incidence and clinical features of Clostridium difficile infection; single center study. Korean Journal of Gastroenterology 2010; 55: 175-182.
12. Lee YJ, et al. Change of Clostridium difficile colitis during recent 10 years in Korea. Korean Journal of Gastroenterology 2010; 55: 169-174.
13. Shin BM, et al. Multicentre study of the prevalence of toxigenic Clostridium difficile in Korea: Results of a retrospective study 2000-2005. Journal of Medical Microbiology 2008; 57: 697-701.
14. Shin BM, et al. Emerging toxin A-B+ variant strain of Clostridium difficile responsible for pseudomembranous colitis at a tertiary care hospital in Korea. Diagnostic Microbiology and Infectious Disease 2008; 60: 333-337.
15. Kim H, et al. Investigation of toxin gene diversity, molecular epidemiology, and antimicrobial resistance of Clostridium difficile isolated from 12 hospitals in South Korea. Korean Journal of Laboratory Medicine 2010; 30: 491-497.
16. Tae CH, et al. The first case of antibiotic-associated colitis by Clostridium difficile PCR ribotype 027 in Korea. Journal of Korean Medical Science 2009; 24: 520-524.
17. McDonald LC, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. New England Journal of Medicine 2005; 353: 2433-2441. (Pubitemid 41770164)
18. Kuijper EJ, et al. Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Eurosurveillance 2008; 13.
19. Kato H, et al. First isolation of Clostridium difficile O27 in Japan. Eurosurveillance 2007; 12: E0701113.
20. Kyne L, et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. New England Journal of Medicine 2000; 342: 390-397. (Pubitemid 30084537)
21. Gravel D, et al. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: A Canadian Nosocomial Infection Surveillance Program Study. Clinical Infectious Disease 2009; 48: 568-576.
22. Dubberke ER, et al. Multicenter study of Clostridium difficile infection rates from 2000 to 2006. Infection Control and Hospital Epidemiology 2010; 31: 1030-1037.
23. Barbut F, et al. A European survey of diagnostic methods and testing protocols for Clostridium difficile. Clinical Infectious Disease 2003; 9: 989-996. (Pubitemid 37361827)
24. Jung SW, et al. Clinical aspects of rifampicin-associated pseudomembranous colitis. Journal of Clinical Gastroenterology 2007; 41: 38-40.
25. Lee JK, et al. Comparative value of sigmoidoscopy and stool cytotoxin-A assay for diagnosis of pseudoemmbranous colitis. Intestinal Research 2005; 3: 61-67.
26. Pepin J, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clinical Infectious Disease 2005; 40: 1591-1597. (Pubitemid 40720808)
27. Schroeder MS. Clostridium difficile-associated diarrhea. American Family Physician 2005; 71: 921-928.
28. Peterson LR, et al. Detection of toxigenic Clostridium difficile in stool samples by real-time polymerase chain reaction for the diagnosis of C. difficile-associated diarrhea. Clinical Infectious Disease 2007; 45: 1152-1160. (Pubitemid 47580313)
29. Delmee M, et al. Laboratory diagnosis of Clostridium difficile-associated diarrhoea: A plea for culture. Journal of Medical Microbiology 2005; 54: 187-191. (Pubitemid 40868006)
30. Cohen SH, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infection Control and Hospital Epidemiology 2010; 31: 431-455.